Invent medic Sweden AB’s (“Invent Medic”) clinical multicenter-study is in its final stretch with all patients recruited. The final patient data are due after the holidays and thereafter will the results be analyzed and compiled into the technical file and CE-process.
Invent medic Sweden AB’s (“invent medic”) clinical study coordinated by senior physician Aino Fianu Jonasson at Karolinska University Hospital in Stockholm is in its final stretch. The last of the 96 patients has been recruited, and data are due after the weekends. Thereafter the results will be processed and together with results from other studies on the product compiled and reviewed by the company's notified Body (NB) before a CE process which is a prerequisite for launching the TVS on the market.
Karin Bryder, CEO of Invent Medic, comments:
“Since we initiated the clinical study of the TVS, we have experienced a great deal of interest from both clinicians and patients. I am pleased to see that the study is now being finalized and I look forward to the results with excitement. “
For more information pleas contact
Karin Bryder, CEO
Phone: +46 (0)70 683 41 44
E-mail: [email protected]
This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21st December 2017.
Invent Medic Sweden AB , Company registration number 556682-1046, has developed a medical device for non-surgical relief of female stress urinary incontinence. The inventors behind the product, Jan Clarén and Lars-Olof Henriksson, have been involved in the development and performance of the surgical method TVT, which is now known as the Golden Standard for surgical treatment of female stress incontinence. The product is based on the same scientific basis and has similar mechanism of action as the surgical method but is based on a non-surgical support and is designed so that the woman can use the product when needed. This product has the potential to satisfy a major medical need and could thus have a significant market value. Invent medic's vision is to offer new and innovative medical devices and treatment methods to women with the goal of improving their health and quality of life. The offer shall include safe, effective and safe products and treatment methods that should be easy to use and which will provide health economic benefits to society. Invent Medic Sweden AB is listed on Aktietorget. Ticker is IMS and the share's ISIN code is SE0007603402. For more information see www.inventmedic.com and www.aktietorget.se
Latest posts by Brad Bennett (see all)
- ImmVRse Collaborates With Imperial College to Lead Research on Impact of VR on Neural Activity - February 17, 2018
- St. Louis Music Upgrades 2,000 Sq. Ft. Trade Show Display With Greatmats Carpet Tiles - February 17, 2018
- Having Trouble With Student Loan Repayment Paperwork? Ameritech Financial Provides Assistance - February 17, 2018